Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Deloitte
Healthtrust
Boehringer Ingelheim
Julphar
Colorcon
Covington
AstraZeneca
Dow

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,871,809

« Back to Dashboard

Which drugs does patent 8,871,809 protect, and when does it expire?

Patent 8,871,809 protects PENNSAID and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.
Summary for Patent: 8,871,809
Title:Diclofenac topical formulation
Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
Inventor(s): Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA)
Assignee: Nuvo Research Inc. (Mississauga, Ontario, CA)
Application Number:14/025,781
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,871,809
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition;

Drugs Protected by US Patent 8,871,809

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma PENNSAID diclofenac sodium SOLUTION;TOPICAL 204623-001 Jan 16, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,871,809

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,101,591 Diclofenac topical formulation ➤ Try a Free Trial
9,168,305 Diclofenac topical formulation ➤ Try a Free Trial
9,220,784 Diclofenac topical formulation ➤ Try a Free Trial
8,252,838 Diclofenac topical formulation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,871,809

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007311019 ➤ Try a Free Trial
Brazil PI0717769 ➤ Try a Free Trial
Canada 2666398 ➤ Try a Free Trial
China 101588791 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Argus Health
Cantor Fitzgerald
Covington
Queensland Health
Cerilliant
Harvard Business School
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.